A Phase 1 Study of ABBV-400 in People With Advanced Solid Tumors


Full Title

A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects with Advanced Solid Tumors


The purpose of this study is to find the highest dose of ABBV-400 to treat advanced cancer. The people in this study have solid tumors that spread (metastasized). In addition, the tumors make too much of a protein called c-MET. High levels of c-MET can cause cancer to grow and spread.

ABBV-400 binds to tumor cells with high levels of c-MET. It is designed to deliver chemotherapy to those cells, stopping tumor growth. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have a cancerous solid tumor that has spread.
  • Have recovered from the serious side effects of prior therapies before receiving ABBV-400.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call 646-888-4226.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID